Patent intelligence · US
US 11753630
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
Patent details — US 11753630
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 12, 2023
- Expiration
- Sep 7, 2043
- Applicant
- Precision BioSciences, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K48/005, A61K48/0058
Quick answer
US 11753630 (Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene) is held by Precision BioSciences, Inc.. Status: granted. Granted Sep 12, 2023. Expires Sep 7, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Precision BioSciences, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K48/005, A61K48/0058
More from Precision BioSciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 11753630?
US 11753630 (Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene) is held by Precision BioSciences, Inc.. Status: granted. Granted Sep 12, 2023. Expires Sep 7, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11753630?
Precision BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 11753630 expire?
Our index shows an expiration date of Sep 7, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.